Keech A C, Harper R W, Harrison P M, Pitt A, McLean A J
Department of Clinical Pharmacology, Alfred Hospital, Melbourne, Victoria, Australia.
Eur J Clin Pharmacol. 1988;35(4):363-6. doi: 10.1007/BF00561365.
Chronic coadministration of oral verapamil with oral atenolol resulted in a variable increase in atenolol steady-state plasma concentrations in a group of 10 patients on chronic maintenance therapy. Individual subjects showed changes in area under the plasma atenolol concentration-time curve (AUC) of more than 100%, however group comparisons did not achieve statistical significance unless normalized for verapamil dose. Renal clearance of atenolol was shown to be decreased by more than 25% in 2 subjects studied using intravenous dosing of atenolol. This interaction is likely to contribute to the documented clinical intolerance of combinations of atenolol and verapamil.
在一组接受慢性维持治疗的10名患者中,口服维拉帕米与口服阿替洛尔长期联合用药导致阿替洛尔稳态血浆浓度出现不同程度的升高。个体受试者的血浆阿替洛尔浓度-时间曲线下面积(AUC)变化超过100%,然而,除非以维拉帕米剂量进行标准化,否则组间比较未达到统计学显著性。在使用阿替洛尔静脉给药研究的2名受试者中,阿替洛尔的肾清除率降低超过25%。这种相互作用可能导致了阿替洛尔与维拉帕米联合用药时临床上已记录的不耐受情况。